Roundup: Nesa gets US FDA 510(k) for fibroid mapping tool and more briefs

Nesa obtains US FDA 510(k) for fibroid mapping tech

Indian femtech Nesa Medtech has received the United States Food and Drug Administration 510(k) clearance for its fibroid mapping tool.

Its Fibroid Mapping Reviewer Application assists in the diagnosis and planning of interventional procedures for patients with uterine fibroids. It generates a 3D model of the uterus from ultrasound images where physicians can locate fibroids and their dimensions. 

AIM collaborates with Stanford Medicine to validate its endoscopic AI 

Tokyo-based startup AI Medical Service (AIM) has signed a joint research agreement with Stanford University School of Medicine to validate its diagnostic endoscopic AI. 

The collaboration intends to check the applicability of the Japanese endoscopic AI in the United States, where 26,000 new cases of gastric cancers are diagnosed each year. A press release noted that incidences are particularly high in immigrant populations, especially East Asians.

Chinese MedGPT claims high practical diagnostic accuracy 

Chinese digital healthcare company Medlinker recently set out to check the accuracy of the medical large-scale language model on its MedGPT service by comparing its diagnostic capability with human doctors.

Introduced in May this year, MedGPT offers intelligent diagnosis and treatment capabilities, providing practical diagnostic value in real medical scenarios. It can also diagnose diseases outside its field of expertise and suggest treatment plans based on other clinical observations and factors.

Its live evaluation involved 120 patients and ten doctors from West China Hospital, Sichuan University. 

Based on the review of their results by seven doctors from major Chinese hospitals, human doctors scored 7.5 out of 10 on average while MedGPT was graded 7.2. The recommendations provided by MedGPT were found to be 96% as good as the human doctors. 

Lunit to power breast cancer screening at major Saudi hospital

South Korean medical AI company Lunit has bagged another contract in Saudi Arabia to deliver its AI solution for cancer diagnosis. 

According to a press release, the company signed a contract with Cloud Solutions, a subsidiary of Dr Sulaiman Al Habib Medical Group (HMG), which is one of the biggest healthcare providers in the Middle East.

Lunit will supply its AI-powered mammography solution, Lunit INSIGHT MMG, to HMG for the next three years. It will be integrated into the diagnosis systems of its 20 medical institutions in the region. 

The partners will also collaborate to enhance the diagnostic support solution using Cloud Solution’s cloud AI platform. 

The new contract closely follows the recent signing of a similar supply deal with Seha Virtual Hospital. Both contracts are expected to contribute to the kingdom’s national cancer screening programme. 

Meanwhile, Lunit will also supply the Lunit INSIGHT DBT, its AI-powered 3D Breast Tomosynthesis analysis solution, to HMG later this year.